US Patent 7,049,328: Deferiprone Cardiac Iron-Overload Claims, Scope, Expiration, and Patent Landscape

US Patent 7,049,328 covered the use of deferiprone to prevent or treat cardiac iron loading in transfusion-dependent patients. Its central distinction was a claimed cardio-preferential effect: reducing or stabilizing iron in the heart, including intracellular cardiac iron, relative to total-body or hepatic iron stores.

The patent issued on May 23, 2006, and its 20-year patent term expired in approximately November 2018, subject to any recorded patent-term adjustment. It therefore does not present a current US patent barrier to generic deferiprone or competing iron-chelation products. Its historical importance was greater than its current blocking value because it supported a disease-specific and organ-specific use of deferiprone in transfusion-dependent patients with cardiac iron overload.

What does US Patent 7,049,328 protect?

The patent protects method-of-treatment claims, not deferiprone as a chemical compound. The active ingredient is deferiprone, also known as 3-hydroxy-1,2-dimethylpyridin-4-one, together with physiologically acceptable salts.

The claim set has five principal elements:

A transfusion-dependent patient.
Cardiac iron overload, iron loading, iron-induced cardiac disease, or risk of cardiac iron overload.
Administration of deferiprone or a physiologically acceptable salt.
A therapeutic result involving stabilization, reduction, chelation, or removal of cardiac iron.
In several claims, a cardio-preferential effect compared with total-body or hepatic iron reduction.

The patent does not require a particular underlying hematologic disease in every independent claim. A patient with transfusion-dependent beta thalassemia would fall within the commercial target population, but the wording can also reach other chronically transfused conditions if the cardiac iron-loading limitations are met.

Claim architecture

Claim group	Main subject matter	Key limitation
Claims 1-5	Treatment, stabilization, or reduction of cardiac iron disease	Transfusion-dependent patient with cardiac iron overload or iron-induced cardiac disease
Claims 6-8	Cardio-preferential iron reduction	Heart iron reduced in preference to liver or general body stores
Claim 9	Intracellular cardiac iron removal	Direct reduction or removal of intracellular cardiac iron
Claim 10	Prevention of cardiac disease	Cardio-preferential efficacy compared with total-body iron reduction
Claims 11-12	Oral administration and oral dosage forms	Excipients permitted in the dosage form
Claims 13-15	Dose ranges	Up to 150 mg/kg/day, up to 125 mg/kg/day, or 25-75 mg/kg/day
Claims 16-17	Routes of administration	Intravenous, transdermal, rectal, oral, buccal, aural; oral administration separately claimed
Claim 18	Sustained release	Sustained-release deferiprone formulation
Claim 19	Comparative chelation	Cardio-preferential function compared with deferoxamine or other chelators
Claim 20	Combination therapy	Deferoxamine administered with deferiprone

Claims 1 through 10 are the principal commercial claims. Claims 11 through 20 narrow the methods by adding route, formulation, dosage, comparative efficacy, or combination-treatment limitations.

How broad are the independent claims?

Claims 1 through 5 are broad in therapeutic objective but narrower in patient population and organ target. They require a transfusion-dependent patient and a cardiac iron condition. A product label limited to general systemic iron overload would not, by itself, establish infringement. The use must be directed to or involve the claimed cardiac condition.

Claims 6 through 10 are more technically distinctive. They require a relationship between cardiac iron removal and iron stores elsewhere in the body. The claims use terms such as:

"in preference to general iron stores"
"in preference to ... the liver"
"direct reduction/removal of intracellular iron stores"
"cardio preferential"
"cardio-selective"

These limitations create both potential value and litigation exposure. They distinguish the invention from ordinary deferiprone chelation, but they also require proof of a cardiac-specific therapeutic effect.

Literal infringement considerations

A likely infringement analysis would examine whether the accused method includes:

A transfusion-dependent patient.
Cardiac iron overload, cardiac iron loading, or a risk of cardiac disease.
Deferiprone administration.
The claimed therapeutic purpose or result.
For claims 6-10 and 19, evidence of preferential cardiac activity.

A generic label that expressly identifies cardiac iron overload or cardiac MRI monitoring could create greater method-of-use risk than a label limited to general transfusional iron overload. Actual infringement would depend on prescribing, physician instructions, patient use, product labeling, and the construction of the disputed functional limitations.

Claims 3 and 4 are potentially broader than claims requiring demonstrated cardiac disease because they refer to a patient "risking iron overload of the heart" or to stabilizing iron-induced heart disease. Claims 6-10 are narrower because they require preferential cardiac reduction or intracellular cardiac iron removal.

What technical concept distinguishes the patent?

The technical concept is organ-selective iron chelation. Deferiprone was known before this patent as an orally active iron chelator. The claimed advance was its use to address cardiac iron accumulation in chronically transfused patients and its alleged ability to reduce myocardial iron more effectively than total-body or hepatic iron stores.

Cardiac iron is clinically important because myocardial iron can produce arrhythmia, systolic or diastolic dysfunction, and heart failure. Serum ferritin and liver iron concentration do not always measure myocardial iron adequately. Cardiac T2* magnetic resonance imaging became an important tool for quantifying myocardial iron and evaluating chelation response.

The strongest technical claims are therefore claims 6-10 and 19. They do not merely claim treating iron overload. They claim a distribution of therapeutic effect among organs, with the heart receiving preferential treatment.

What are the principal claim-construction and validity issues?

The patent’s enforceability would have depended heavily on how a court construed its functional language.

"Cardio-preferential" and "cardio-selective"

These terms may require a comparison between cardiac efficacy and reduction of total-body, hepatic, or other iron stores. The comparison could involve:

Change in cardiac T2*.
Change in liver iron concentration.
Cardiac iron concentration measured by imaging or biopsy.
Clinical cardiac outcomes.
Relative chelation activity in myocardial versus hepatic tissue.

The claims do not establish a single required measurement method. That creates potential disputes over whether the terms are definite and whether the specification provides adequate guidance.

"Direct reduction/removal of intracellular iron stores"

Claim 9 is narrower but potentially difficult to prove. A claimant would need evidence that deferiprone removes intracellular myocardial iron rather than merely lowering circulating iron or total-body iron.

"Sufficient to reduce" and "sufficient to stabilize"

These are therapeutic-result limitations. They generally permit variation in dose and response, but they can require proof that the treatment achieved the claimed result or was administered with the purpose of achieving it.

Enablement and written description

Potential validity challenges could focus on whether the patent supported the full breadth of:

All transfusion-dependent patient populations.
All listed administration routes.
All doses up to 150 mg/kg/day.
Sustained-release formulations.
Physiologically acceptable salts.
Cardio-preferential activity over all alternative chelators.
Intracellular cardiac iron removal.

The claims cover many routes and formulations, while the invention’s commercial evidence is most closely associated with oral deferiprone. A validity challenge could argue that the specification did not demonstrate or enable the full scope across every claimed route and formulation.

Obviousness

The likely obviousness theory would combine:

Prior deferiprone iron-chelation disclosures.
Known cardiac toxicity from transfusional iron overload.
Prior use of deferoxamine and other chelators for iron overload.
Clinical or imaging evidence concerning myocardial iron.

The patent’s counterargument would be that cardiac and hepatic iron behave differently and that deferiprone’s cardio-preferential effect was not predictable from its general chelation activity.

When did US Patent 7,049,328 expire?

Event	Approximate date
Earliest priority	November 1997
US patent application period	1998-1999
US publication	2001
Patent grant	May 23, 2006
Base 20-year term expiration	Approximately November 2018
Current status	Expired; no present exclusionary right

The patent term was calculated from the relevant US nonprovisional or international filing framework, not from the grant date. The 2006 grant did not create a new 20-year period beginning in 2006.

A complete freedom-to-operate review should confirm the USPTO Patent Center record for the exact patent-term-adjustment calculation and any terminal disclaimer. On the available patent chronology, the patent is no longer enforceable in the United States.

What was the FDA and Orange Book status?

Ferriprox is the US brand for deferiprone. The FDA approved Ferriprox in 2011 for patients with transfusional iron overload due to thalassemia syndromes when current chelation therapy was inadequate. The FDA later approved additional dosage forms, including oral tablets and oral solution [2].

The US regulatory position is separate from the 7,049,328 patent:

Regulatory item	Status
Active ingredient	Deferiprone
Brand	Ferriprox
Original US sponsor	ApoPharma USA Corp.
FDA pathway	New Drug Application
Initial US approval	2011
Therapeutic area	Transfusional iron overload
Dosage forms	Oral tablets and oral solution
Patent at issue	Historical method-of-use patent
Current patent barrier from US 7,049,328	None after expiration

The patent’s cardiac claims are not equivalent to the full FDA-approved label. FDA approval permits treatment of transfusional iron overload in the approved population. The patent claims were narrower in one respect because they focused on cardiac iron, but broader in other respects because they covered multiple routes, doses, salts, formulations, and comparative therapeutic concepts.

Whether US Patent 7,049,328 was listed in the Orange Book for a specific Ferriprox NDA must be determined from the relevant annual Orange Book and patent-listing records. A patent can be important to a product’s development history without creating a current Orange Book-based stay or automatic generic-entry block.

Were there Paragraph IV challenges to this patent?

A Paragraph IV certification applies to a patent listed for an approved drug product and challenged by an abbreviated new drug application. The practical significance of such a challenge depends on:

Whether the patent was listed for the NDA.
Whether the patent was still unexpired when the ANDA was filed.
Whether the patent claimed the approved use or dosage form.
Whether the NDA holder filed an infringement action within 45 days.
Whether a 30-month stay applied.

No present Paragraph IV barrier arises from US Patent 7,049,328 because the patent term has ended. A historical Paragraph IV challenge, if any, would have had commercial significance only before approximately November 2018. The patent’s method-of-use structure could also have reduced ANDA exposure if an applicant used a permitted skinny label that omitted the patented cardiac indication.

The available record does not establish a commercially material, reported US infringement case involving this patent. The patent should therefore be treated as an expired historical right rather than an active litigation obstacle.

What formulations and dosage regimens are protected?

The patent claims oral dosage forms, oral administration, excipients, sustained-release products, and dose ranges. The key dosage limitations are:

Up to 150 mg/kg/day.
Up to 125 mg/kg/day.
25-75 mg/kg/day.
Daily administration.

These claims do not require a particular tablet strength, excipient, particle size, polymorph, release profile, or manufacturing process. Claim 18 reaches sustained-release formulations, but it depends on the broader cardiac-treatment claims.

The patent therefore did not create a strong standalone formulation estate. It protected the use of a formulation in the claimed cardiac setting. A separate formulation patent would generally be needed to block a product based on tablet composition, liquid stability, modified release, taste masking, crystal form, or manufacturing process.

How does deferiprone compare with deferoxamine and deferasirox?

Attribute	Deferiprone	Deferoxamine	Deferasirox
Chemical class	Oral small-molecule chelator	Hexadentate chelator	Oral tridentate chelator
Administration	Primarily oral	Usually parenteral infusion	Oral
Cardiac iron relevance	Central to US 7,049,328	Established chelation comparator	Used for transfusional iron overload
Patent at issue	Cardio-preferential treatment method	Separate historical patent estate	Separate formulation and method estate
Generic/biosimilar category	Small-molecule generic	Small-molecule generic	Small-molecule generic
Main commercial differentiation	Oral use and myocardial iron activity	Long clinical history, parenteral delivery	Oral dosing and once-daily convenience

Deferiprone’s competitive position was strongest where oral treatment and myocardial iron reduction were clinically important. Deferoxamine was a comparator in claim 19 and claim 20. Deferasirox was a competing chelator but is not expressly named in the claims provided.

No biosimilar pathway applies. Deferiprone, deferoxamine, and deferasirox are chemically synthesized small molecules. Competitive entry proceeds through generic-drug pathways, not through biosimilar applications under the Public Health Service Act.

Which companies and products created competitive risk?

The principal commercial participants were:

ApoPharma, the original Ferriprox sponsor and patent-commercialization participant.
Chiesi Farmaceutici, which acquired ApoPharma and its portfolio.
Novartis, associated with Exjade and Jadenu deferasirox products.
Manufacturers of deferoxamine products, including generic suppliers.
Generic deferiprone manufacturers pursuing abbreviated approval.

The main competitive risk shifted after patent expiration from patent litigation to regulatory substitution, manufacturing economics, pharmacovigilance, and market access.

Licensing and commercialization

The patent and deferiprone program were associated historically with ApoPharma’s commercialization activities. The commercial rights later moved within the Chiesi group through its acquisition of ApoPharma. That transaction affected ownership and commercialization of Ferriprox-related assets, but it did not revive or extend the expired US patent term.

No continuing license can create enforceable exclusivity after patent expiration unless supported by a separate unexpired patent, regulatory exclusivity, contract, trade secret, or other independent right.

What manufacturing and intellectual-property barriers remain?

US Patent 7,049,328 does not provide a current manufacturing barrier. It does not claim:

A new deferiprone molecule.
A unique salt as a standalone composition.
A specific polymorph.
A proprietary synthetic route.
A tablet composition independent of use.
A stable oral solution independent of use.
A device or delivery system.

Remaining barriers may include:

FDA approval requirements.
Bioequivalence testing.
Quality controls for deferiprone and impurities.
Oral-solution stability and packaging.
Labeling and pharmacovigilance obligations.
Separate unexpired formulation or process patents.
Trade secrets relating to manufacturing scale-up.
Market access and physician adoption.

These are commercial and regulatory barriers, not continuing rights under the expired patent.

What generic launch scenarios existed?

The principal historical scenarios were:

Full-label launch

A generic applicant could seek approval for the full approved indication. Before patent expiration, this could have created method-of-use litigation risk if the product label included cardiac iron-overload treatment.

Skinny-label launch

An applicant could omit a patented cardiac indication from its label while retaining noninfringing indications. This strategy would have reduced, but not necessarily eliminated, risk if physicians continued prescribing the product for the patented use.

Post-expiration launch

After approximately November 2018, the patent no longer supported an injunction or damages claim for ordinary post-expiration conduct. Entry then depended on FDA approval, exclusivity, supply capability, and commercial positioning.

How strong was the patent estate?

The patent estate was strong in historical differentiation but weak as a current exclusionary asset.

Factor	Assessment
Core therapeutic concept	Distinctive
Chemical composition protection	None in this patent
Cardiac-use protection	Broad in claims 1-5
Preferential cardiac effect	Valuable but proof-intensive
Formulation protection	Narrow, dependent, and use-limited
Dose protection	Moderate but dependent
Manufacturing protection	None apparent
Current US enforceability	None after expiration
Biosimilar protection	Not applicable
Generic-entry risk today	High from a patent perspective

The strongest claims were those covering cardiac iron reduction in transfusion-dependent patients. The weakest commercial claims were the route, formulation, and dose limitations because they remained dependent on the underlying cardiac-use limitations and did not independently protect a product.

Key Takeaways

US Patent 7,049,328 covered deferiprone treatment for cardiac iron overload in transfusion-dependent patients.
Its central technical concept was cardio-preferential or cardio-selective iron reduction.
Claims 1-5 broadly covered treatment and stabilization of cardiac iron disease.
Claims 6-10 focused on preferential cardiac, myocardial, or intracellular iron reduction.
Claims 11-20 added oral administration, dosage ranges, routes, sustained release, comparative efficacy, and deferoxamine combination therapy.
The patent was a method-of-use patent, not a composition-of-matter or manufacturing patent.
Its US term expired in approximately November 2018.
It presents no current US patent barrier to generic deferiprone.
Deferiprone is an FDA-approved small-molecule chelator marketed as Ferriprox.
Biosimilar risk is irrelevant; generic-drug competition is the applicable framework.
Current commercial barriers are regulatory, manufacturing, quality, supply, and market-access issues rather than this expired patent.

FAQs

Does US Patent 7,049,328 cover deferiprone itself?

No. It covers specified methods of using deferiprone for cardiac iron loading and iron-induced cardiac disease. It does not claim deferiprone as a chemical compound.

Does the patent cover deferiprone for liver iron overload?

Not as a standalone treatment. The claims require cardiac iron loading, cardiac iron disease, risk of cardiac iron overload, or a cardio-preferential effect.

Can a generic deferiprone manufacturer use the same dose range?

Yes, the expired patent no longer blocks use of the claimed dose range. A generic applicant must still satisfy FDA approval and labeling requirements.

Is Ferriprox protected by a biosimilar exclusivity period?

No. Ferriprox is a small-molecule drug, so generic-drug rules apply rather than biosimilar rules.

Does the patent block deferasirox or deferoxamine?

No. It claims methods using deferiprone. Deferasirox and deferoxamine are separate active ingredients with separate regulatory and patent histories.

References

United States Patent and Trademark Office. (2006). U.S. Patent No. 7,049,328, Use of deferiprone for treatment of iron induced cardiac disease. U.S. Department of Commerce.
U.S. Food and Drug Administration. (2011). Ferriprox (deferiprone) prescribing information. FDA.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
Pennell, D. J., Berdoukas, V., Karagiorga, M., Ladis, V., Piga, A., Porter, J. B., Voskaridou, E., Gossios, T., Plata, E., & Tao, J. (2006). Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with myocardial iron loading. Blood, 107(9), 3738-3744.
Chiesi Farmaceutici S.p.A. (2023). Ferriprox: Product and prescribing information. Chiesi USA.

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Canada	2313270	Jun 30, 2000

PCT Information
PCT Filed	June 28, 2001	PCT Application Number:	PCT/CA01/00956
PCT Publication Date:	January 10, 2002	PCT Publication Number:	WO02/02114

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	427107	⤷ Start Trial
Australia	2001270402	⤷ Start Trial
Australia	7040201	⤷ Start Trial
Brazil	0112280	⤷ Start Trial
Canada	2313270	⤷ Start Trial
China	101380322	⤷ Start Trial
China	101933924	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 7,049,328

Summary for Patent: 7,049,328